1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeted molecular profiling of circulating cell-free DNA in patients with advanced hepatocellular carcinoma
    Journal Article

    Cowzer, D.; White, J. B.; Chou, J. F.; Chen, P. J.; Kim, T. H.; Khalil, D. N.; El Dika, I. H.; Columna, K.; Yaqubie, A.; Light, J. S.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Gemcitabine, docetaxel, capecitabine, cisplatin, irinotecan as first-line treatment for metastatic pancreatic cancer
    Journal Article

    Wilbur, H. C.; Durham, J. N.; Lim, S. J.; Purtell, K.; Bever, K. M.; Laheru, D. A.; De Jesus-Acosta, A.; Azad, N. S.; Wilt, B.; Diaz, L. A.; more...
    Cancer Research Communications (2023)

    Fulltext@MSK | Save
  • GABA regulates electrical activity and tumor initiation in melanoma
    Journal Article

    Tagore, M.; Hergenreder, E.; Perlee, S. C.; Cruz, N. M.; Menocal, L.; Suresh, S.; Chan, E.; Baron, M.; Melendez, S.; Dave, A.; more...
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Efficacy of BRAF inhibitor plixorafenib (Fore8394) in recurrent, primary central nervous system tumors (PCNST)
    Meeting Abstract

    de la Fuente, M.; Butowski, N.; Taylor, J.; Yaeger, R.; Tsai, F. Y. C.; Janku, F.; Allen, C.; Ammakkanavar, N.; Michelson, G.; Jiang, P.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Genomic characteristics and clinical outcomes of stereotactic radiosurgery for colorectal cancer brain metastases
    Meeting Abstract

    Gui, C.; Walch, H.; Mueller, K.; Eichholz, J.; Khatri, I.; Del Balzo, L.; Kemeny, N.; Imber, B.; Schultz, N.; Foote, M.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2— , locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; van Cutsem, E.; Gallego Plazas, J.; Huang, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
    Meeting Abstract

    Oh, D. Y.; Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Omori, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Chan, S. L.; Sangro, B.; Kelley, R. K.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E. N.; Furuse, J.; Kang, Y. K.; Galle, P. R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Yanez Weber, P. E.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup
    Meeting Abstract

    Yoshino, T.; André, T.; Kim, T. W.; Yong, W. P.; Shiu, K. K.; Vittrup Jensen, B.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save